UK-US pharma deal risks 230,000 deaths

A new trade agreement between the US and UK aims to increase the UK's pharmaceutical spending, but an analysis warns it could cost the NHS billions and result in over 200,000 avoidable deaths in England by diverting funds from vital health services. The deal involves boosting spending on new medicines and avoiding tariffs, but critics argue it may primarily benefit multinational drug companies rather than the NHS. The analysis highlights potential negative impacts on health outcomes unless the UK allocates additional funding.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل